Humoral and cellular responses to SARS-CoV-2 vaccines before and after chimeric antigen receptor-modified T-cell therapy

Blood Adv. 2023 May 9;7(9):1849-1853. doi: 10.1182/bloodadvances.2022008338.

Authors

Michael A Gonzalez^{1

2}, Atif M Bhatti¹, Kristin Fitzpatrick¹, Jim Boonyaratanakornkit^{1

2}, Meei-Li Huang³, Victoria L Campbell³, Jessica Hecht¹, Sarah Ibrahimi¹, Shera N Wanner², Damian J Green^{1

2}, David G Maloney^{1

2}, Jordan Gauthier^{1

2}, Andrew J Cowan^{1

2}, Alexander L Greninger³, Elizabeth M Krantz¹, David M Koelle^{1

2

3

4

5}, Joshua A Hill^{1

2}

Affiliations

¹ Fred Hutchinson Cancer Center, Vaccine and Infectious Disease Division, Seattle, WA.
² Department of Medicine, University of Washington, Seattle, WA.
³ Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA.
⁴ Department of Global Health, University of Washington, Seattle, WA.
⁵ Department of Translational Research, Benaroya Research Institute, Seattle, WA.

No abstract available

MeSH terms

COVID-19 Vaccines
COVID-19* / prevention & control
Cell- and Tissue-Based Therapy
Humans
Receptors, Chimeric Antigen* / genetics
SARS-CoV-2

Substances

COVID-19 Vaccines
Receptors, Chimeric Antigen